Improvements in breast cancer survival between 1995 and 2012 in Denmark: The importance of earlier diagnosis and adjuvant treatment

References

• Engholm G , Ferlay J , Christensen N , Bray F , Gjerstorff ML , Klint A , et al . NORDCAN-a Nordic tool for cancer information, planning, quality control and research. Acta Oncol 2010; 49: 725– 36.
   PubMed Web of Science ®Google Scholar
• Christiansen P , Vejborg I , Kroman N , Holten I , Garne JP , Vedsted P , et al . Position paper: Breast cancer screening, diagnosis, and treatment in Denmark. Acta Oncol 2014; 53: 433– 44.
   PubMed Web of Science ®Google Scholar
• Blichert-Toft M , Nielsen M , Düring M , Møller S , Rank F , Overgaard M , et al . Long-term results of breast conserving surgery versus mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG- 82TM protocol. Acta Oncol 2008; 47: 672– 81.
   PubMed Web of Science ®Google Scholar
• NIH consensus conference. Treatment of early-stage breast cancer. JAMA 1991; 265: 391– 5.
   PubMed Web of Science ®Google Scholar
• Tvedskov TF , Jensen MB , Balslev E , Ejlertsen B , Kroman N. Stage migration after introduction of sentinel lymph node dissection in breast cancer treatment in Denmark: A nationwide study. Eur J Cancer 2011; 47: 872– 8.
   PubMed Web of Science ®Google Scholar
• Houssami N , Macaskill P , Marinovich ML , Morrow M. The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: A meta-analysis. Ann Surg Oncol 2014; 21: 717– 30.
   PubMed Web of Science ®Google Scholar
• Overgaard M , Hansen PS , Overgaard J , Rose C , Andersson M , Bach F , et al . Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997; 337: 949– 55.
   PubMed Web of Science ®Google Scholar
• Overgaard M , Jensen MB , Overgaard J , Hansen PS , Rose C , Andersson M , et al . Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999; 353: 1641– 8.
   PubMed Web of Science ®Google Scholar
• Darby S , Mcgale P , Correa C , Taylor C , Arriagada R , Clarke M , et al . Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15- year breast cancer death: Meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet 2011; 378: 1707– 16.
   PubMed Web of Science ®Google Scholar
• Mcgale P , Taylor C , Correa C , Cutter D , Duane F , Ewertz M , et al . Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014; 383: 2127– 35.
   PubMed Web of Science ®Google Scholar
• Christiansen P , Bjerre K , Ejlertsen B , Jensen MB , Rasmussen BB , Lænkholm AV , et al . Mortality rates among early-stage hormone receptor-positive breast cancer patients: A population-based cohort study in Denmark. J Natl Cancer Inst 2011; 103: 1363– 72.
   PubMedGoogle Scholar
• Davies C , Godwin J , Gray R , Clarke M , Cutter D , Darby S , et al . Early Breast Cancer Trialists Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771– 84.
   PubMed Web of Science ®Google Scholar
• Davies C , Pan H , Godwin J , Gray R , Arriagada R , Raina V , et al . Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381: 805– 16.
   PubMed Web of Science ®Google Scholar
• Dowsett M , Forbes JF , Bradley R , Ingle J , et al . Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials. Lancet 2015; 386: 1341– 52.
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ , Procter M , Leyland-Jones B , Goldhirsch A , Untch M , Smith I , et al . Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659– 72.
   PubMed Web of Science ®Google Scholar
• Perez EA , Romond EH , Suman VJ , Jeong J-H , Sledge G , Geyer CE , et al . Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. J Clin Oncol 2014; 32: 3744– 52.
   PubMed Web of Science ®Google Scholar
• Peto R , Davies C , Godwin J , Gray R , Pan HC , Clarke M , et al . Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet 2012; 379: 432– 44.
   PubMed Web of Science ®Google Scholar
• Ejlertsen B , Jensen M-B , Mouridsen HT. Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer. Acta Oncol 2014; 53: 174– 85.
   PubMed Web of Science ®Google Scholar
• Møller S , Jensen M-B , Ejlertsen B , Bjerre KD , Larsen M , Hansen HB , et al . The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol 2008; 47: 506– 24.
   PubMed Web of Science ®Google Scholar
• Charlson ME , Pompei P , Ales KL , Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40: 373– 83.
   PubMedGoogle Scholar
• Land LH , Dalton SO , Jensen M-B , Ewertz M. Influence of comorbidity on the effect of adjuvant treatment and age in patients with early-stage breast cancer. Br J Cancer 2012; 107: 1901– 7.
   PubMed Web of Science ®Google Scholar
• Anderson WF , Rosenberg PS , Petito L , Katki Ha , Ejlertsen B , Ewertz M , et al . Divergent estrogen receptor-positive and -negative breast cancer trends and etiologic heterogeneity in Denmark. Int J Cancer 2013; 133: 2201– 6.
   PubMed Web of Science ®Google Scholar
• Berry D , Cronin K , Plevritis SK , Fryback DG , Clarke L , Zelen M , et al . Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353: 1784– 92.
   PubMed Web of Science ®Google Scholar
• Elkin EB , Hudis C , Begg CB , Schrag D. The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999. Cancer 2005; 104: 1149– 57.
   PubMed Web of Science ®Google Scholar
• Park J , Anderson WF , Gail MH. Improvements in US Breast Cancer Survival and Proportion Explained by Tumor Size and Estrogen-Receptor Status. J Clin Oncol 2015; 33: 2870– 6.
   PubMed Web of Science ®Google Scholar